Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Z Qian

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|April 28, 2006
Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug targetCurtis R Chong, David Z Qian, Fan Pan, et al.
Cancer Research|September 18, 2004
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584David Z Qian, Xiaofei Wang, Sushant K Kachhap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cellsAnne Myrthue, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Journal of Medicinal Chemistry|May 30, 2015
Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer ActivityFuchun Xie, Bingbing X Li, Alina Kassenbrock, et al.
Cancer Research|September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alphaDavid Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitorsHenk M W Verheul, Brenda Salumbides, Karen Van Erp, et al.
The Journal of Biological Chemistry|August 22, 2012
HIF1α protein stability is increased by acetylation at lysine 709Hao Geng, Qiong Liu, Changhui Xue, et al.
The Prostate|December 10, 2025
Prostate Cancer Cells With the AR-Low and EMT-High Phenotype Are Vulnerable to NAD+ Synthesis InhibitorsHyun-Kyung Ko, Rebecca L Foertsch, Kasen Shi, et al.
The Prostate|January 15, 2005
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cellsDavid Z Qian, Mingqiang Ren, Yongfeng Wei, et al.
The Prostate|April 11, 2025
Understanding Enzalutamide-Resistance Based on a Functional Single-Cell ApproachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|April 28, 2006
Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug targetCurtis R Chong, David Z Qian, Fan Pan, et al.
Cancer Research|September 18, 2004
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584David Z Qian, Xiaofei Wang, Sushant K Kachhap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cellsAnne Myrthue, Brooks L S Rademacher, Janet Pittsenbarger, et al.
Journal of Medicinal Chemistry|May 30, 2015
Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer ActivityFuchun Xie, Bingbing X Li, Alina Kassenbrock, et al.
Cancer Research|September 5, 2006
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alphaDavid Z Qian, Sushant K Kachhap, Spencer J Collis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitorsHenk M W Verheul, Brenda Salumbides, Karen Van Erp, et al.
The Journal of Biological Chemistry|August 22, 2012
HIF1α protein stability is increased by acetylation at lysine 709Hao Geng, Qiong Liu, Changhui Xue, et al.
The Prostate|December 10, 2025
Prostate Cancer Cells With the AR-Low and EMT-High Phenotype Are Vulnerable to NAD+ Synthesis InhibitorsHyun-Kyung Ko, Rebecca L Foertsch, Kasen Shi, et al.
The Prostate|January 15, 2005
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cellsDavid Z Qian, Mingqiang Ren, Yongfeng Wei, et al.
The Prostate|April 11, 2025
Understanding Enzalutamide-Resistance Based on a Functional Single-Cell ApproachChanghui Xue, Hyun-Kyung Ko, Kasen Shi, et al.
Pageof 5